CytomX Therapeutics, Inc. (Nasdaq: CTMX) — Point-in-Time Research (as of 2026-11-01)

Company profile: CytomX is a clinical-stage, oncology-focused biopharmaceutical company based in South San Francisco, operating on its masked, conditionally activated PROBODY® platform, with a pipeline that includes varsetatug masetecan (Varseta-M; CX-2051) and CX-801 [2]. As of the latest data the stock traded around USD 2.24–2.34, with a market capitalization near USD 500–522 million [5][10][11][18].

Key recent catalysts (last ~1–3 months)